

- Competition Act** *see* Monopolies—Abuse
- Competition Tribunal Act (Bill C-91)(1st Sess., 33rd Parl.)** *see* Patent Act (amdt.)(Bill C-22)—References, Amending
- Compulsory licensing, 11:15**  
 Legislation, business maximum freedom test, 8:26-7  
 Patent protection/socially optimal mix, providing, 8:60; 9:45  
*See also* Agricultural chemicals; Ayerst Laboratories;  
 Biotechnology industry; Brand name drugs—Exclusivity period from imports; Drugs and pharmaceuticals—Costs/prices—Tagamet/cimetidine; Drugs and pharmaceuticals industry; Economic Council of Canada; Generic drugs; Health care; High technology centres—Western Canada; Hoffman-LaRoche Limited; Patent Act; Universities—Research and development
- Connaught Laboratories** *see* Diabetes—Research
- Connors, Kathleen** (National Federation of Nurses' Unions)  
 Patent Act (amdt.)(Bill C-22), 9:3, 23-32, 34-9
- Constitution** *see* Drug Prices Review Board
- Consumer and Corporate Affairs Department**  
 Andre, Bill C-22 cost impact studies, information requested, 11:61; 15:59; 16:14  
 M. (Dingwall), 13:32-5, negated on recorded division, 3  
 Canadian Patent Office, computerizing, 16:43  
 Publication, *Patenting Life Forms and Processes*, 16:58  
*See also* Drugs and pharmaceuticals—Costs/prices; Witnesses
- Consumer Price Index** *see* Drugs and pharmaceuticals—Costs/prices
- Consumers**  
 Market choices, restrictions, prescription drugs/IUD examples, 6:15-8, 24  
*See also* Drug Prices Review Board; Drugs and pharmaceuticals—Costs/prices; Drugs and pharmaceuticals industry—Compulsory licensing
- Consumers Association of Canada**  
 Advocacy role, 6:29-30  
 Market-based philosophy, fund-raising appeal letter, etc., 6:30-3  
*See also* Drugs and pharmaceuticals—Costs/prices; Witnesses
- Continental Pharma Cryosan, 15:67**
- Coopers and Lybrand** *see* Drugs and pharmaceuticals—Costs/prices, Canadian Drug Manufacturers Association
- Copyright** *see* Drug patents
- Côté, Hon. Michel**  
 References, 16:13
- Cott, Alfred** (Kidney Foundation of Canada)  
 Patent Act (amdt.)(Bill C-22), 13:3, 8-11, 14
- Council of Canadians** *see* Committee—Witnesses, Inviting
- Croft, W.D.** (Calgary Research and Development Authority)  
 Patent Act (amdt.)(Bill C-22), 5:4, 33-46
- Cyclosporin** *see* Drugs and pharmaceuticals
- Cystic fibrosis**  
 Causes, treatment, etc., 9:10-2, 14-5, 17-8, 20-2  
 Provincial drug programs, 9:21  
 Socialized medicine, life expectancy prolonging, 9:11, 33-4
- Dalhousie University Medical School**  
 Legislation, Bill C-22, opposing, Dickson letter to McInnes, etc., 11:17, 41-2; 12:9-10, 36-7; 15:13, 38
- Dan, Leslie** (Canadian Drug Manufacturers Association)  
 Patent Act (amdt.)(Bill C-22), 3:3, 14-8, 22, 27-8, 32-3, 36, 40
- Daniels, Mark** (Consumer and Corporate Affairs Department)  
 Patent Act (amdt.)(Bill C-22), 16:3, 7, 18-9, 33, 40, 61-4, 69, 76-7, 82
- Davidson, Roy** *see* Free trade, Canada-United States negotiations
- Delmar Chemicals Division of Canada Packers Inc.** *see* Drugs and pharmaceuticals industry—Montreal, Que.
- Denmark** *see* Drug patents—Abolishing
- Detail men** *see* Brand name drugs—Exclusivity period from imports—*De facto* extension
- Deterrent fees** *see* Drugs and pharmaceuticals—Costs/prices
- Diabetes**  
 Drug therapy advances, insulin, etc., 1:22-3; 14:52-3  
 Research, Connaught Laboratories' discovery, 15:67
- Dialysis**  
 Drug costs, etc., 13:6
- Dickson, Prof. Howard** *see* Dalhousie University Medical School
- Diltiazem hydrochloride, 17:49-50**
- Dingwall, Dave** (L—Cape Breton—East Richmond)  
 American Association of Retired Persons, 12:21  
 Antoft, references, 11:8  
 Biotechnology, 12:45  
 Biotechnology industry, 8:38-40, 53; 12:46  
 Brand name drugs, 3:13-4, 54, 64-5; 5:16, 32; 6:38-9, 78; 7:8; 8:21, 53; 9:13-4; 10:13-5, 40; 11:9, 41-3, 70; 12:7-9, 32-4, 47; 13:11-2, 22-5, 41-2; 14:12-3; 15:9-11, 21, 34-5, 93; 16:82-5; 17:22, 24  
 Calgary Research and Development Authority, 5:45  
 Canadian Automobile Workers Union, 14:23  
 Canadian Cardiovascular Society, 14:10  
 Canadian Chamber of Commerce, 8:19  
 Canadian Drug Manufacturers Association, 3:13-4  
 Canadian Federation of Biological Societies, 11:9; 12:10  
 Canadian Health Coalition, 7:7  
 Canadian Society for Clinical Investigation, 12:34  
 Canadian Society of Industrial Pharmacists, 15:33  
 Cangene Corp., 8:39, 41  
 Community Health Co-operative Federation of Saskatchewan, 11:70  
 Consumer and Corporate Affairs Department, M., 13:32-5  
 Dalhousie University Medical School, 11:17, 41; 12:9  
 Disabled and handicapped, 15:76-7  
 Drug patents, 11:10-1; 16:26-8, 39-42, 46, 49-54, 56, 62, 65  
 Drug plans, 6:22; 8:54; 12:21, 55, 68; 13:23; 14:11; 15:57-8, 75  
 Drug Prices Review Board, 3:28-9, 35, 73-4; 5:15-6, 26-7, 31-2; 6:13-5, 22-4, 53, 64-5; 7:9; 8:9, 21; 9:27; 11:24-5, 70-1; 12:47, 55-7, 67; 13:12-3, 22, 24; 14:26; 15:10, 22-3, 35-6, 50-1, 58-9, 77-8, 93; 16:66-8, 71-3, 76; 17:26-7, 32-4, 36-9, 41  
 Drugs and pharmaceuticals, 3:27, 36, 53-4, 64; 6:20-1, 39-40; 6:52-3, 65, 77-8; 9:27-8, 46; 10:23-5, 39; 11:56-8, 70-1; 12:21-2, 57; 14:11-2, 38; 15:21-3, 35, 58, 92-4; 16:14-6  
 Drugs and pharmaceuticals industry, 3:12, 28, 34-5, 54-5, 64-5; 5:14; 7:7-8; 9:45; 10:12-3, 41-2; 11:9-10, 43-4; 14:10, 23-4; 15:34, 59  
 Free enterprise system, 12:56; 15:36